Why does sermorelin dosing differ from synthetic HGH?
Sermorelin is a growth hormone-releasing hormone (GHRH) analog — a 29-amino-acid peptide that mimics the natural GHRH signal the hypothalamus sends to the pituitary. When you administer sermorelin, you are not adding growth hormone to your system directly. You are prompting your pituitary gland to produce and secrete growth hormone on its own.
This has an important implication for dosing: the amount of GH your pituitary releases in response to a given sermorelin dose depends on your pituitary’s own functional reserve and sensitivity. Two patients receiving the same dose may have meaningfully different IGF-1 responses. This is why lab monitoring — specifically IGF-1 levels — is central to sermorelin dose management. A fixed dose without lab follow-up is flying blind.
What is a typical starting sermorelin dosage?
The consensus starting range across most physician-supervised sermorelin protocols is 100–200 mcg injected subcutaneously once daily, administered approximately 30–60 minutes before sleep. The initiation dose is conservative for two reasons:
- Unknown pituitary sensitivity: Starting low and measuring IGF-1 after 4–8 weeks reveals how responsive your pituitary is. Some patients respond well to 100 mcg; others need 200–300 mcg to see meaningful IGF-1 movement.
- Side effect minimization: Higher sermorelin doses can cause transient flushing, headache, or injection-site reactions. These are typically mild but are more common at higher starting doses.
Your prescribing clinician sets your specific starting dose after reviewing your intake assessment, baseline labs, and health history. The ranges described here are typical — not universal.
Why is sermorelin injected before bed?
Growth hormone secretion is pulsatile — it doesn’t flow continuously but is released in discrete bursts, with the largest burst occurring in the first few hours of deep (slow-wave) sleep. This is a conserved feature of human physiology, documented across multiple decades of neuroendocrine research.
Administering sermorelin before bed positions the peptide to amplify this natural nocturnal GH pulse. When sermorelin is active in the bloodstream as the pituitary enters its highest-activity secretory window, the result is a physiologically timed boost to the GH pulse rather than an arbitrary off-schedule stimulation.
This timing also keeps the administration window consistent, which matters for IGF-1 measurement. IGF-1 blood draws are typically taken in the morning after a full night on the medication, giving a stable post-dose snapshot rather than a variable midday reading.
How do clinicians use IGF-1 labs to adjust the dose?
IGF-1 (insulin-like growth factor 1) is the primary downstream marker used to calibrate sermorelin dosage. The liver produces IGF-1 in response to growth hormone stimulation, so IGF-1 levels serve as an integrated measure of GH activity over time — smoother than measuring GH itself, which fluctuates minute to minute.
After 4–8 weeks at the starting dose, your clinician will order an IGF-1 panel. The interpretation framework looks something like this:
| IGF-1 Result | Likely Clinician Response |
|---|---|
| Low / below mid-range for age | Increase dose; retest in 4–8 weeks |
| Mid-range for age | Maintain current dose; reassess symptoms |
| High / above range for age | Reduce dose to prevent over-stimulation |
Note that “optimal” IGF-1 is not the same as the highest possible value. The goal is to support IGF-1 within a range that reflects healthy physiology for your age — not to push it to the ceiling. Supraphysiologic IGF-1 carries its own risks, and responsible sermorelin protocols avoid it.
What are the common sermorelin dose-adjustment scenarios?
Dose increase: 200 mcg to 300–400 mcg
If IGF-1 has not moved significantly after 8 weeks at 200 mcg, a clinician may step up to 300 or 400 mcg. Some patients — particularly older adults with reduced pituitary sensitivity — need higher doses to achieve meaningful IGF-1 elevation. The increase is made incrementally and followed by re-testing.
Dose reduction: managing over-response
Patients who respond strongly to even the initiation dose may see IGF-1 rise above the target range on 200 mcg. In this case, reducing to 100 mcg or even less-frequent dosing (5 days on, 2 days off) is preferable to maintaining a dose that elevates IGF-1 unnecessarily.
Cycling: intermittent vs. continuous protocols
Some protocols use a cycle structure — typically 5 days on, 2 days off, or monthly breaks — to prevent pituitary desensitization and allow natural GH pulsatility to reassert. Other clinicians prefer continuous dosing with periodic dose holidays. The evidence base for either approach is not definitive; your clinician’s protocol preference will be guided by your individual response over time.
Where is compounded sermorelin sourced, and is it good quality?
Sermorelin is a Tier 1 peptide at PepScribe — meaning it has a clearly defined regulatory pathway for compounding. Sermorelin originally received FDA approval as a diagnostic agent for GH deficiency (Geref), and licensed 503Acompounding pharmacies in the United States can legally prepare it for patient-specific use under a clinician’s prescription.
All compounded sermorelin prescribed through PepScribe is prepared in the USA by licensed 503A pharmacies. No hidden overseas supply chain. Sermorelin is a peptide that degrades under improper storage conditions — which is one of several reasons why gray-market or overseas sources carry real product-quality risks beyond just regulatory concerns.
Frequently asked questions
What is a typical sermorelin dosage?
Most physician-supervised sermorelin protocols start between 100 and 200 mcg injected subcutaneously once daily, typically before bed. The starting dose is conservative and adjusted upward based on lab response (IGF-1) and how the patient feels after 4–8 weeks.
Why is sermorelin taken at night?
Growth hormone is released in pulses, with the largest pulse occurring in the first several hours of deep sleep. Administering sermorelin before bed allows it to amplify the body's natural nocturnal growth hormone release rather than stimulating at an off-cycle time. This timing principle is a core feature of sermorelin protocols and distinguishes it from synthetic GH administration.
How long does sermorelin take to work?
Most patients do not notice significant changes in the first two to four weeks. Meaningful improvements in sleep quality, recovery, and energy typically emerge over 8–12 weeks. Body composition changes, if they occur, tend to be gradual and may take three to six months of consistent use to become apparent.
How does a clinician adjust sermorelin dosage?
Clinicians use a combination of IGF-1 blood testing and symptom assessment to guide dose adjustments. If IGF-1 levels remain low after 4–8 weeks and symptoms are unchanged, a dose increase may be indicated. If IGF-1 rises into the optimal range and symptoms improve, the current dose is maintained. Excessive IGF-1 elevation prompts a dose reduction.
Is there a maximum sermorelin dosage?
There is no universally agreed maximum dose, but most protocols do not exceed 500 mcg per day. Pushing above therapeutic IGF-1 levels offers no additional benefit and increases the risk of side effects including water retention, joint discomfort, and numbness. Lab monitoring prevents inadvertent over-dosing.
Can sermorelin be dosed more than once per day?
Some protocols use twice-daily dosing — once before bed and once in the early morning — to capture multiple natural GH pulse windows. This is less common at initiation and is a clinical decision based on individual response. Most patients begin with once-nightly dosing and adjust from there.